Williams Keryn A, Coster Douglas J
Department of Ophthalmology, Flinders University, Adelaide, Australia.
Transplantation. 2007 Oct 15;84(7):806-13. doi: 10.1097/01.tp.0000285489.91595.13.
Corneal allotransplantation is highly successful in the short term, but much less successful in the longer term. Many corneal grafts in recipients with corneal neovascularization or the sequelae of ocular inflammation undergo irreversible rejection, despite topical immunosuppression with glucocorticosteroids. Sensitization to cornea-derived alloantigen proceeds by both direct and indirect routes, but the anatomic location of sensitization remains unclear. Multiple and redundant mechanisms operate in the effector phase of corneal graft rejection, which is largely cell-mediated rather than antibody-mediated. Human leukocyte antigen matching may improve outcomes in high-risk patients but systemic immunosuppression is frequently ineffective and is seldom used.
角膜同种异体移植在短期内非常成功,但从长期来看成功率要低得多。许多患有角膜新生血管或眼部炎症后遗症的受者,尽管使用糖皮质激素进行局部免疫抑制,其角膜移植仍会发生不可逆的排斥反应。对角膜来源的同种异体抗原的致敏通过直接和间接途径进行,但致敏的解剖位置仍不清楚。多种冗余机制在角膜移植排斥的效应阶段起作用,这在很大程度上是细胞介导的,而非抗体介导的。人类白细胞抗原配型可能会改善高危患者的预后,但全身免疫抑制通常无效,很少使用。